BB Biotech: Change in TecDax
(Thomson Reuters ONE) -
BB BIOTECH AG /
BB Biotech: Change in TecDax
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
BB Biotech is being replaced in the TecDax Index due to a decline in its Xetra
trading volumes as a percentage of total/worldwide trading volumes. Trading
volumes on SIX Swiss Exchange have increased in recent months and this has led
to a decline in the relative share of trading volumes conducted on Xetra.
Since its admission to the TecDax in March 2003 BB Biotech has - apart from a
brief interlude - been a constant member of Germany's technology index. After
the latest index review the Deutsche Börse announced yesterday that BB Biotech
would be replaced and no longer included in the index as of June 22, 2015.
Besides market capitalization and trading volumes, companies like BB Biotech
whose shares are listed on multiple exchanges must meet an additional criterion
to qualify for inclusion in the TecDax: At least 33% of their global trading
volumes must be conducted on Xetra or the Frankfurt stock exchange.
While BB Biotech claims a top ranking on the TecDax in terms of market
capitalization and a mid-field position as measured by trading volume, the
relative share of its Xetra trading volumes has fallen below the minimum
threshold.
Trading volume is subject to regional fluctuations that can be traced to general
investor demand. An increase in trading volumes on SIX Swiss Exchange in recent
months has led to a decline in Xetra's relative share of total trading volumes.
As historical trading data shows, trading volumes can shift back in favor of the
German trading platform, which would be in the interests of BB Biotech.
For further information:
Investor Relations
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, Tel.
+41 44 267 67 00
Dr. Silvia Schanz, ssc(at)bellevue.ch
Maria-Grazia Iten-Alderuccio, mga(at)bellevue.ch
Claude Mikkelsen, cmi(at)bellevue.ch
Media Relations
b-public AG, Pfingstweidstrasse 6, 8005 Zurich, Switzerland, Tel.
+41 79 423 22 28
Thomas Egger, teg(at)b-public.ch
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, Tel.
+41 44 267 67 00
Tanja Chicherio, tch(at)bellevue.ch
www.bbbiotech.com
Company profile
BB Biotech invests in companies in the fast growing market of biotechnology and
is one of the world's largest investors in this sector with more than CHF 3.7
billion in assets under management. BB Biotech is listed in Switzerland, Germany
and Italy. Its investments are focused on listed companies that are developing
and commercializing novel medical treatments and cures. BB Biotech's investment
selection process is guided by the fundamental research and analysis of
physicians and molecular biologists. Its Board of Directors has many years of
experience in industry and science.
Disclaimer
This release contains forward-looking statements and expectations as well as
assessments, beliefs and assumptions. Such statements are based on the current
expectations of BB Biotech, its directors and officers, and are, therefore,
subject to risks and uncertainties that may change over time. As actual
developments may significantly differ, BB Biotech and its directors and officers
accept no responsibility in that regard. All forward-looking statements
included in this release are made only as of the date of this release and BB
Biotech and its directors and officers assume no obligation to update any
forward-looking statements as a result of new information, future events or
other factors.
Press Release (PDF):
http://hugin.info/130285/R/1926360/691374.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: BB BIOTECH AG via GlobeNewswire
[HUG#1926360]
Datum: 04.06.2015 - 18:28 Uhr
Sprache: Deutsch
News-ID 398365
Anzahl Zeichen: 4869
contact information:
Town:
Schaffhausen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 153 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"BB Biotech: Change in TecDax"
steht unter der journalistisch-redaktionellen Verantwortung von
BB BIOTECH AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
